Objectives: To analyze outcomes of patients > 85 years with de novo bladder cancer (BCa). To compare outcomes of high grade (HG) non-muscle invasive BCa (NMIBC) treated with standard therapies versus palliative management. Methods: Retrospective revision of 65 patients > 85 years who underwent transurethral resection of the bladder (TURB) for de novo BCa. According to functional status each patient was offered a standard or palliative management after TURB. Results: Median age was 87.3 years (85.2–95.4) and 51 were men (78.5%). Twenty-eight (43%) were American Society of Anesthesiologists (ASA) II and 37 ASA III–IV (57%). Pathological examination: 29 pTx-pTa (44.6%), 28 pT1 (43.1%) and 8 pT2 (12.3%). Twenty were low grade (30.8%) and 45 HG (69.2%). Among 37 HG NMIBC patients, 43% followed standard therapies (BCG or re-staging TURB + BCG), and 57% a palliative management (no oncological treatments). With a median follow-up of 20 months (3–108), 2 (12.5%) died in standard group compared to 11 (52.4%) in palliative. In univariate analysis, age (p = 0.024), stage (p = 0.009), and standard management (p = 0.019) were related to overall survival (OS). In multivariate, standard management was an independent prognostic factor of OS (hazard ratio 0.164, 95% CI 0.036–0.744, p = 0.048). Conclusions: Advanced age should not be a contraindication for standard therapies in BCa. A geriatric assessment could identify patients who may benefit from adjuvant therapies after TURB.

Keywords:
Bladder cancer, Transurethral resection, Complication, Bacillus calmette-guérin, Intravesical instillation
1.
Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world.
World J Urol
. 2009 Jun; 27(3): 289–93.
2.
Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al.; EUROCARE-5 Working Group. Urinary tract cancer survival in Europe 1999-2007: results of the population-based study EUROCARE-5.
Eur J Cancer
. 2015 Oct; 51(15): 2217–30.
3.
Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly.
Urol Oncol
. 2009 Nov-Dec; 27(6): 653–67.
4.
Centers for Disease Control and Prevention. Available at www.cdc.gov/aging. Accessed on December 16, 2008.
5.
Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th ed. Wiley-Blackwell; 2009.
6.
Sauter G, Amin M. Tumours of the urinary system: non-invasive urothelial neoplasias.
WHO classification of classification of tumours of the urinary system and male genital organs
. Lyon: IARCC Press; 2004.
7.
Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR. Late age (85 years or older) peak incidence of bladder cancer.
J Urol
. 2008 Apr; 179(4): 1302–5.
8.
Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy.
Urol Oncol
. 2008 Mar-Apr; 26(2): 137–40.
9.
Izquierdo L, Peri L, Leon P, Ramírez-Backhaus M, Manning T, Alcaraz A, et al. The role of cystectomy in elderly patients - a multicentre analysis.
BJU Int
. 2015 Oct; 116 Suppl 3: 73–9.
10.
Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, et al.; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy.
Eur Urol
. 2007 Mar; 51(3): 699–706.
11.
Eredics K, Bretterbauer KM, Comploj E, Friedl A, Gschliesser T, Lenart S, et al. Bladder cancer in nonagenarians: a multicentre study of 123 patients.
BJU Int
. 2018 Dec; 122(6): 1010–5.
12.
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al.; Task Force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
Crit Rev Oncol Hematol
. 2005 Sep; 55(3): 241–52.
13.
Kenis C, Decoster L, Flamaing J, Debruyne PR, De Groof I, Focan C, et al. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.
Ann Oncol
. 2018 Sep; 29(9): 1987–94.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.